Clinical development of new prophylactic antimalarial drugs after the 5th Amendment to the Declaration of Helsinki

Therapeutics and Clinical Risk Management

Volumn 4, Issue 4, 2008, Pages 803-819

  Dow, Geoffrey S ^a   Magill, Alan J ^a   Ohrt, Colin ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Declaration of Helsinki; DH2000; Ethics; Malaria; Prophylaxis; Treatment

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; AZITHROMYCIN; CHLOROQUINE; CHLOROQUINE PLUS PROGUANIL; DIHYDROARTEMISININ; DOXYCYCLINE; FANSIDAR; MEFLOQUINE; PIPERAQUINE; PLACEBO; PRIMAQUINE; TAFENOQUINE;

CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ESOPHAGITIS; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HEALTH CARE POLICY; HIGH RISK POPULATION; HUMAN; MALARIA; MALARIA FALCIPARUM; MEDICAL ETHICS; MORTALITY; NONHUMAN; PATENT; PATIENT COMPLIANCE; PLASMODIUM OVALE; PLASMODIUM VIVAX; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION;

EID: 52949108806     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. Anon. 2002. Fair benefits for research in developing countries. Science, 298:2133-4.
2. Baird JK, Basri H, Subianto B, et al. 1995. Treatment of chloroquine-resistant Plasmodium vivax with chloroquine and primaquine or halofantrine. J Infect Dis, 171:1678-82.
3. Baird JK, Lacey MD, Basri H, et al. 2001. Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia. Clin Infect Dis, 22:1990-7.
4. Baird J, Schwartz E, Hoffman S. 2007. Prevention and treatment of vivax malaria. Curr Infect Dis Rep, 9:39-46.
5. Bautista CT, Chan AS, Ryan JR, et al. 2006. Epidemiology and spatial analysis of malaria in the Northern Peruvian Amazon. Am J Trop Med Hyg, 75:1216-22.
6. Bejon P, Andrews L, Anderson RF, et al. 2005. Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. J Infect Dis, 191:619-26.
7. Berman JD, Neilsen R, Chulay JD, et al. 2001. Causal prophylactic efficacy of atovaquone-proguanil (Malarone™) in a human challenge model. Trans R Soc Med Hyg, 95:429-32.
8. Bill and Melinda Gates Foundation. 2007. Eradication of malaria [online]. Accessed November 28, 2007. URL: http://www.gatesfoundation.org/MediaCenter/Speeches/Co-ChairSpeeches/ BillgSpeeches/BGSpeech-MalariaForum-071017.htm.
9. Biomarkers Definitions Working Group. 2001. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther, 69:89-95.
10. Blackmer J, Haddad H. 2005. The Declaration of Helsinki: an update on paragraph 30. CMAJ, 173:9.
11. Boggild AK, Parise ME, Lewis LS, et al. 2007. Atovaquone-proguanil: report from the CDC expert meeting on malaria chemoprophylaxis (II). Am J Trop Med Hyg, 76:208-23.
12. Brueckner RP, Coster T, Wesche DL, et al. 1998a. Prophylaxis of Plasmodium falciparum infection in a human challenge model with WR 238605, a new 8-aminoquinoline antimalarial. Antimicrob Agents Chemo, 42:1293-4.
13. Brueckner RP, Lasseter KC, Lin ET. 1998b. First-time-in humans safety and pharmacokinetics of WR238605, a new antimalarial. Am J Top Med Hyg, 58:645-9.
14. Brueckner RP, Ohrt C, Baird JK, et al. 2001. 8-Aminoquinolines. In: Rosenthal PJ (ed). Antimalarial chemotherapy: Mechanisms of action, resistance, and new directions in drug discovery. New Jersey: The Humana Press, Inc.
15. Bryan JP. 2006. Cost considerations of malaria chemoprophylaxis including use of primaquine for primary or terminal chemoprophylaxis. Am J Trop Med Hyg, 75:416-50.
16. Carlson RV, Boyd KM, Webb DJ. 2004. The revision of the Declaration of Helsinki: past, present and future. Br J Clin Pharmacol, 57:695-73.
17. Chandramohan D, Owusu-Agyei S, Carneiro I, et al. 2005. Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana. BMJ, 331:727-33.
18. Chen LH, Keystone JS. 2005. New strategies for the prevention of malaria in travelers. Infect Dis Clin N Am, 19:185-210.
19. Chen LH, Wilson ME, Schlagenhauf P. 2006. Prevention of malaria in long-term travelers. JAMA, 296:2234-4.
20. Christen D, Steffen R, Schlagenhauf P. 2006. Deaths caused by malaria in Switzerland 1988-2002. Am J Trop Med Hyg, 75:1188-94.
21. Church LW, Le TP, Bryan JP, et al. 1997. Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge. J Infect Dis, 175:915-20.
22. Davis TM, Hung TY, Sim IK, et al. 2005. Piperaquine: a resurgent antimalarial drug. Drugs, 65:75-87.
23. Druilhe P, Pradier O, Parent G, et al. 1986. Levels of antibodies to Plasmodium sporozoite surface antigens reflect malaria transmission and are persistent in the absence of reinfection. Infect Immun, 53:393-7.
24. Dunachie, SJ, Walther M, Epstein JE. 2006. A DNA prime-modified vaccinia virus Ankara boost vaccine encoding thrombospondin-related adhesion protein but no circumsporozoite protein partially protects healthy malaria-naïve adults against Plasmodium falciparum sporozoite challenge. Infect Immun, 74:5933-42.
25. Dunne MW, Singh N, Shukla M, et al. 2005. A multicenter study of azithromycin, alone and in combination with chloroquine, for the treatment of acute uncomplicated Plasmodium falciparum malaria in India. J Infect Dis, 191:1582-8.
26. Edstein MD, Kotecka BM, Anderson KL, et al. 2005. Lengthy antimalarial activity of atovaquone in human plasma following atovaquone-proguanil administration. Antimicr Agents Chemo, 49:4421-2.
27. Egan A, Crawley J, Schellenberg D, et al. 2005. Intermittent preventive treatment for malaria control in infants: moving towards evidence-based policy and public health action. Trop Med Int Health, 10:815-17.
28. Emmanuel EJ, Miller FG. 2001. The ethics of placebo-controlled trials-a middle ground. N Engl J Med, 345:915-19.
29. Forster HP, Emanuel E, Grady C. 2001. The 2000 revision of the Declaration of Helsinki: a step forward or more confusion. Lancet, 259:1449-53.
30. Geerligs PD, Brabin BJ, Eggelte TA. 2003. Analysis of the effects of malaria chemoprophylaxis in children on haematological responses, morbidity and mortality. Bull World Health Organ, 81:205-16.
31. GlaxoSmithKline. 2004. Malaronel (atovaquone-proguanil) [prescribing information]. Research Triangle Park, NC: GlaxoSmith Kline.
32. Greenwood BM. 1989. The microepidemiology of malaria and its importance to malaria control. Trans R Soc Trop Med Hyg, 83:25-9.
33. Greenwood BM, David PH, Otoo-Forbes, et al. 1995. Mortality and morbidity from malaria after stopping malaria chemoprophylaxis. Trans R Soc Trop Med Hyg, 89:629-33.
34. Hale BR, Owusu-Agyei S, Fryauff DJ, et al. 2003. A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum. Clin Infect Dis, 36:541-9.
35. Hasugian AR, Purba HL, Kenangalem E, et al. 2007. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and post-treatment prophylaxis against multi-drug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin Inf Dis, 44:1067-74.
36. Heppner DG, Kester KE, Ockenhouse CF. 2005a. Toward an RTS, S-based, multi-stage, multiantigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine, 17-18:2243-50.
37. Heppner DG, Walsh DS, Uthaimongkol N, et al. 2005b. Randomized, controlled double-blind trial of daily oral azithromycin in adults for the prophylaxis of Plasmodium vivax malaria in Western Thailand. Am J Trop Med Hyg, 73:842-9.
38. Hill DR, Baird JK, Parise ME, et al. 2006. Primaquine: Report from CDC expert meeting on malaria chemoprophylaxis. Am J Trop Med Hyg, 75:401-15.
39. Hogh B, Clarke PD, Camus D, et al. 2000. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travelers: a randomized, double blind study. Lancet, 356:1888-94.
40. Kious BM. 2001. The Nuremburg Code: Its history and implications. Princeton J Bioethics, 4:7-19.
41. La Vaque TJ, Rossiter T. 2001. The ethical use of placebo controls in clinical research: The Declaration of Helsinki. App Psychophysiol Biofeedback, 26:23-37.
42. Lapierre DI, Duparc S. 2007. The industry perspective on the Declaration of Helsinki. Congress of International Society of Tropical Medicine, 2007, Vancouver, Canada. Abstract SY0602.
43. Legros F, Bouchaud O, Ancelle T, et al. 2007. Risk factors for imported fatal Plasmodium falciparum malaria, France, 1996-2003. Emerg Infect Dis, 13:883-8.
44. Lell B, Kuckner D, Ndjave M, et al. 1999. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet, 351:709-13.
45. Lell B, Faucher JF, Misinou MA, et al. 2000. Malaria chemoprophylaxis with tafenoquine: a randomized study. Lancet, 355:2041-5.
46. Lie RK, Emanuel E, Grady C, et al. 2004. The standard of care debate: the Declaration of Helsinki versus the international consensus opinion. J Med Ethics, 30:190-3.
47. Ling J, Baird JK, Fryauff DJ, et al. 2002. Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia. Clin Infect Dis, 35:825-33.
48. Looareesuwan S, Chulay JD, Canfield CJ. 1999. Malarone™ (atovaquone and proguanil hydrochloride): A review of its clinical development for the treatment of malaria. Am J Trop Med Hyg, 60:533-41.
49. Macate E, Aide P, Aponte JJ, et al. 2006. Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: a randomized, placebo-controlled trial. J Infect Dis, 194:276-85.
50. Macklin R. 2001. After Helsinki: unresolved issues in international research. Kennedy Inst Ethics J, 11: 17-36.
51. Magill AJ. 2004. Malaria: Epidemiology and risk to the traveler. In: Keystone J, Kozarsky P, Freedman D, et al. (eds). Travel medicine. Chapter 12. Edinburgh, Scotland: Mosby.
52. Marra F, Salzman JR, Ensom MHH. 2003. Atovaquone-proguanil for prophylaxis and treatment of malaria. Ann Pharmacother, 37:1266-75.
53. Menendez C, Kahigwa E, Hirt R, et al. 1997. Randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis for prevention of severe anemia and malaria in Tanzanian infants. Lancet, 350:844-50.
54. Milhous WK. 2001. Development of new drugs for chemoprophylaxis of malaria. Med Trop, 61:48-50.
55. Miller FG, Grady C. 2001. The ethical challenge of infection-inducing challenge experiments. Clin Infect Dis, 33:1028-33.
56. Miller KD, Lobel HO, Satriale RF, et al. 1986. Severe cutaneous reactions among American travellers taking pyrimethamine-sulfadoxine (Fansidar) for malaria prophylaxis. Am J Trop Med Hyg, 35:451-58.
57. Miller RS, Wongsrichanalai C, Buathong N, et al. 2006. Effective treatment of uncomplicated Plasmodium falciparum malaria with azithromycin-quinine combinations: a randomized, dose-ranging study. Am J Top Med Hyg, 73:401-6.
58. Muentener P, Schlagenhauf P, Steffen R. 1999. Imported malaria (1985-1995): Trends and perspectives. Bull World Health Org, 77:560-66.
59. Nasveld P, Brennan L, Kitchener S, et al. 2002a. A randomised, double-blind comparative study to evaluate the safety, tolerability and effectiveness of tafenoquine and mefloquine for the prophylaxis of malaria in non-immune Australian soldiers [abstract]. Annual Meeting of the Americal Society of Tropical Medicine and Hygiene, 2002. Abstract 326.
60. Nasveld P, Kitchener S, Edstein M, et al. 2002b. Comparison of tafenoquine WR238605 and primaquine in the post exposure (terminal) prophylaxis of vivax malaria in Australian Defense Forces Personnel. Trans R Soc Trop Med Hyg, 96:683-4.
61. Newman RD, Parise ME, Barber AM, et al. 2004. Malaria-related deaths among U.S. travelers, 1963-2001. Ann Intern Med, 141:547-55.
62. Noedl H, Krudsood S, Chalermatrana K, et al. 2006. Azithromycin combination therapy with artesunate or quinine for the treatment of uncomplicated Plasmodium falciparum malaria in adults: a randomized, phase 2 clinical trial in Thailand. Clin Infect Dis, 43:1264-71.
63. Nosten F. 2000. Prophylactic effect of Malarone against malaria: all good news? Lancet, 356:1864-5.
64. Novartis. 2006. Novartis accelerates production of life-saving malaria treatment Coartem [online]. Accessed June 15, 2007. URL: http://hugin.info/134323/R/1030389/165274.pdf.
65. Ohrt C, Doolan D, Brice G, et al. 2007. Plasmodium antibodies as surrogate markers of malaria exposure. 5th European Congress on Tropical Medicine and International Health, Amsterdam, Netherlands, May 2007.
66. Ohrt C, Richie TR, Widjaja H, et al. 1997. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double-blind, placebo-controlled trial. Ann Intern Med, 126:963-72.
67. O'Meara WP, Breman JG, McKenzie FE. 2005. The promise and potential challenges of intermittent preventive treatment for malaria in infants (IPTi). Malar J, 4:3.
68. Orlandi-Pradines E, Penhoat K, Durand C, et al. 2006. Antibody responses to several malaria pre-erythrocytic antigens as a marker of malaria exposure among travelers. Am J Trop Med Hyg, 74:979-85.
69. Overbosch D, Schilthuis H, Bienzle U, et al. 2001. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in non-immune travelers: Results from a randomized double-blind study. Clin Infect Dis, 33:1015-21.
70. Peters W. 1999. The evolution of tafenoquine: antimalarial for a new millennium? J R Soc Med, 92:345-52.
71. Peterson E. 2004. Malaria chemoprophylaxis: when should we use it and what are the options? Expert Rev Anti Infect Ther, 2:119-32.
72. Reynolds T. 2000. The ethics of placebo-controlled trials. Ann Intern Med, 133:491.
73. Riis P. 2003. Thirty years of bioethics: the Helsinki Declaration 1964-2003. New Rev Bioethics, 1:15-5.
74. Ritzhaupt L, Betley BA, Hirsch, et al. 2007. Safety assessment of azithromycin plus chloroquine for the treatment and prevention of malaria [abstract]. 56th Annual Meeting of the American Society of Tropical Medicine and Hygiene, 2007, Philadelphia, USA. 517.
75. Rosen JB, Breman JG. 2004. Malaria intermittent preventive treatment in infants, chemoprophylaxis, and childhood vaccinations. Lancet, 363:1386-8.
76. Sanofi-Synthelabo. 1999.: Primaquine brand of phosphate tablet [product information]. Sanofi-Synthelabo, New York.
77. Schellenberg D, Menendez C, Kahigwa E, et al. 2001. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet, 357:1471-7.
78. Schellenberg D, Cisse B, Menendez C, et al. 2006. The IPTi Consortium: research for policy and action. Trends Parasitol, 22:296-300.
79. Simon R. 2000. Are placebo-controlled clinical trials ethical or needed when alternative treatment exists? Ann Intern Med, 133:474-5.
80. Shanks GD, Gordon DM, Klotz FW, et al. 1998. Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria. Clin Infect Dis, 27:494-9.
81. Shanks GD, Ragama BO, Aloo AJ. 1999. Time to reappearance of malaria parasites following various drug treatment regimens in a holoendemic area of western Kenya. Trans R Soc Trop Med Hyg, 93:304-5.
82. Shanks GD, Kain KC, Keystone JS. 2001a. Malaria chemoprophylaxis in the age of drug resistance. II. Drugs that may be available in the future. Clin Infect Dis, 33:381-5.
83. Shanks GD, Oloo AJ, Aleman GM, et al. 2001b. A new primaquine analog, tafenoquine (WR238605), for prophylaxis against Plasmodium falciparum malaria. Clin Infect Dis, 33:1968-74.
84. Shanks GD, Edstein MD. 2005. Modern malaria prophylaxis. Drugs, 65:1091-2110.
85. Shanks GD, Magill AJ, Freedman DO. 2007. Drug free holidays: Pre-travel versus during travel malaria prophylaxis. Am J Trop Med Hyg, 77:1-2.
86. Shapiro TA, Ranasinha CD, Kumar N, et al. 1999. Prophylactic activity of atovaquone against Plasmodium falciparum in humans. Am J Trop Med Hyg, 60:831-6.
87. Shretta R, Brugha R, Robb A, et al. 2000. Sustainability, affordability and equity of corporate drug donations: the case of Malarone. Lancet, 355:1718-20.
88. Shretta R, Walt G, Brugha R, et al. 2001. A political analysis of corporate drug donations: the example of Malarone in Kenya. Health Policy Plan, 16:161-70.
89. Sukwa TY, Mulenga M, Chisdaka N, et al. 1999. A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone™ (atovaquone/proguanil) for the prophylaxis of malaria in Zambia. Am J Trop Med Hyg, 60:521-5.
90. Taylor WR, Richie TL, Fryauff DJ, et al. 1999. Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia. Clin Infect Dis, 28:74-81.
91. [UNFPA] United Nations Food Program. 2007. State of world population 2007. United Nations Population Fund, New York, New York.
92. [USAID] United States Agency for International Development. 2007. President's malaria initiative [online]. Accessed November 28, 2007. URL http://www.fightingmalaria.gov/.
93. [USCDC] United States Center for Diseases Control and Prevention. 2008. CDC health information for international travel 2008 [online]. Accessed July 11, 2007. URL: http://wwwn.cdc.gov/travel/contentYellowBook.aspx.
94. [USFDA] United States Food and Drug Administration. 2000. FDA approves Malarone for prevention and treatment of malaria" [online]. Accessed June 15, 2007. URL: http://www.fda.gov/bbs/topics/ANSWERS/ANS01026.html.
95. [USFDA] United States Food and Drug Administration. 2001. Guidance for industry: Acceptance of foreign clinical studies [online]. Accessed July 11, 2007. URL: http://www.fda.gov/cder/guidance/fstud.pdf.
96. [USFDA] United States Food and Drug Administration. 2005. Guidance for industry: Pharmacogenomic data submissions. United States Department of Health and Human Services, Rockville, MD, United States.
97. [USFDA] United States Food and Drug Administration. 2007. Malaria: Developing drug and non-vaccine products for treatment and prophylaxis (draft guidance for industry). United States Department of Health and Human Services, Rockville, MD.
98. [USCEDER] Center for Drug Evaluation and Research. 2007. Frequently asked questions on drug development and investigational new drug applications [online]. Accessed November 14, 2007. URL http://www.fda.gov/cder/about/smallbiz/faq.htm#Introduction.
99. van der Berg JD, Duvenage CS, Roskell NS, et al. 1999. Safety and efficacy of atovaquone and proguanil hydrochloride for the prophylaxis of Plasmodium falciparum malaria in South Africa. Clin Ther, 21:741-9.
100. Verhage DF, Telgt DS, Bousema JT, et al. 2005. Clininal outcome of experimental human malaria induced by Plasmodium falciparum-infected mosquitoes. Neth J Med, 63:52-8.
101. Wagner JA, Williams SA, Webster CJ. 2007. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther, 81:104-7.
102. Walsh DS, Looareesuwan S, Wilairatana P, et al. 1999. Randomized dose-ranging study of the safety and efficacy of WR 238605 (tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand. J Infect Dis, 180:1282-7.
103. Walsh DS, Wilaratana P, Tang DB, et al. 2004. Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse. Clin Infect Dis, 39:1095-103.
104. Walther M, Thompson FM, Dunachie S, et al. 2006. Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein. Infect Immun, 74: 2706-16.
105. Wang R, Richie TL, Baraceros MF, et al. 2005. Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites. Infect Immun, 73:2863-72.
106. Weiss WR, Oloo AJ, Johnson A, et al. 1995. Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil. J Infect Dis, 171:1671-82.
107. [WMA] World Medical Association. 2004. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects [online]. Accessed June 15, 2007. URL: http://www.wma.net/e/Policy/b3.htm.
108. [WHO] World Health Organization. 2005. World Malaria Report 2005. World Health Organization, Geneva.